Precision Nanosystems NanoAssemblr series microfluidic-based nanoparticle manufacturing platform

Click2Contact

While nanoparticles, composed of polymers or lipids, can be used to deliver pharmaceutical drugs, they are traditionally made by extrusion or sonication — which can be labour-intensive and prone to batch-to-batch variations. To make the transition from bench to clinic, nanoparticle manufacturing methods need to be both reproducible and scalable.

The NanoAssemblr platform from Precision NanoSystems offers microfluidic-based technologies to introduce formulation opportunities that, in addition to being scalable, provide extensive control over the size optimisation and manufacturing process. There is a choice of three systems to accelerate nanomedicine development.

The NanoAssemblr Spark offers drug screening and disease target identification via cell transfection. It manufactures 25–250 µL per run.

The NanoAssemblr Benchtop is suitable for rapid nanomedicine candidate development. It manufactures 1–15 mL per run.

The NanoAssemblr Blaze is suitable for larger preclinical testing of nanomedicines and early chemistry, manufacturing and controls investigation. It manufactures 10–1000 mL per run.

Applications and types of formulations include: protein delivery and screening; nucleic acid delivery and screening; nanoparticle design; targeted drug delivery; lipid nanoparticles; liposomes; and polymeric nanoparticles.